WordNet
- respiratory disease characterized by inflammation of the lung parenchyma (excluding the bronchi) with congestion caused by viruses or bacteria or irritants
- of or relating to the staphylococcus bacteria; "a staphylococcal infection"
PrepTutorEJDIC
- 肺炎
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 入院を要する成人における市中肺炎の治療 treatment of community acquired pneumonia in adults who require hospitalization
- 2. 成人における院内感染性／人工呼吸器関連／医療関連肺炎の治療 treatment of hospital acquired ventilator associated and healthcare associated pneumonia in adults
- 3. 成人における市中肺炎の疫学、病因、および微生物学 epidemiology pathogenesis and microbiology of community acquired pneumonia in adults
- 4. 黄色ブドウ球菌菌血症の合併症 complications of staphylococcus aureus bacteremia
- 5. 小児における侵襲的メチシリン耐性黄色ブドウ球菌感染の治療 treatment of invasive methicillin resistant staphylococcus aureus infection in children
English Journal
- Treatment of infections due to resistant Staphylococcus aureus.
- Anstead GM, Cadena J, Javeri H.Author information Medicine Service, South Texas Veterans Health Care System, San Antonio, TX, USA.AbstractThis chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and multidrug-resistant S. aureus, we have seven effective drugs in clinical use for which little resistance has been observed: vancomycin, quinupristin-dalfopristin, linezolid, tigecycline, telavancin, ceftaroline, and daptomycin. However, vancomycin is less effective for infections with MRSA isolates that have a higher MIC within the susceptible range. Linezolid is probably the drug of choice for the treatment of complicated MRSA skin and soft tissue infections (SSTIs); whether it is drug of choice in pneumonia remains debatable. Daptomycin has shown to be non-inferior to either vancomycin or β-lactams in the treatment of staphylococcal SSTIs, bacteremia, and right-sided endocarditis. Tigecycline was also non-inferior to comparator drugs in the treatment of SSTIs, but there is controversy about whether it is less effective than other therapeutic options in the treatment of more serious infections. Telavancin has been shown to be non-inferior to vancomycin in the treatment of SSTIs and pneumonia, but has greater nephrotoxicity. Ceftaroline is a broad-spectrum cephalosporin with activity against MRSA; it is non-inferior to vancomycin in the treatment of SSTIs. Clindamycin, trimethoprim-sulfamethoxazole, doxycycline, rifampin, moxifloxacin, and minocycline are oral anti-staphylococcal agents that may have utility in the treatment of SSTIs and osteomyelitis, but the clinical data for their efficacy is limited. There are also several drugs with broad-spectrum activity against Gm-positive organisms that have reached the phase II and III stages of clinical testing that will hopefully be approved for clinical use in the upcoming years: oritavancin, dalbavancin, omadacycline, tedizolid, delafloxacin, and JNJ-Q2. Thus, there are currently many effective drugs to treat resistant S. aureus infections and many promising agents in the pipeline. Nevertheless, S. aureus remains a formidable adversary, and despite our deep bullpen of potential therapies, there are still frequent treatment failures and unfortunate clinical outcomes. The following discussion summarizes the clinical challenges presented by MRSA, the clinical experience with our current anti-MRSA antibiotics, and the gaps in our knowledge on how to use these agents to most effectively combat MRSA infections.
- Methods in molecular biology (Clifton, N.J.).Methods Mol Biol.2014;1085:259-309. doi: 10.1007/978-1-62703-664-1_16.
- This chapter reviews data on the treatment of infections caused by drug-resistant Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA). This review covers findings reported in the English language medical literature up to January of 2013. Despite the emergence of resistant and
- PMID 24085702
- Molecular analysis of staphylococcal superantigens.
- Salgado-Pabón W, Case-Cook LC, Schlievert PM.Author information Department of Microbiology, University of Iowa Carver College of Medicine, Iowa City, IA, USA.AbstractStaphylococcal superantigens (SAgs) comprise a large family of exotoxins produced by Staphylococcus aureus strains. These exotoxins are important in a variety of serious human diseases, including menstrual and nonmenstrual toxic shock syndrome (TSS), staphylococcal pneumonia and infective endocarditis, and recently described staphylococcal purpura fulminans and extreme pyrexia syndrome. In addition, these SAg exotoxins are being increasingly recognized for their possible roles in many other human diseases, such as atopic dermatitis, Kawasaki syndrome, nasal polyposis, and certain autoimmune disorders. To clarify the full spectrum of human diseases caused by staphylococcal SAgs, it is necessary to have assays for them. At present there are 23 characterized, serologically distinct SAgs made by S. aureus: TSS toxin-1(TSST-1); staphylococcal enterotoxins (SEs) A, B (multiple variant forms exist), C (multiple minor variant forms exist), D, E, and G; and SE-like H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, and X. The most straightforward way to analyze S. aureus strains for SAgs is through polymerase chain reaction for their genes; we provide here our method for this analysis. Although it would be ideal to confirm that all of the same SAgs are produced by S. aureus strains that have the genes, antibody reagents for SAg detection are only available for TSST-1; SEs A-E and G; and enterotoxin-like proteins H, I, Q, and X. We provide a Western immunoblot procedure that allows in vitro quantification of these SAgs.
- Methods in molecular biology (Clifton, N.J.).Methods Mol Biol.2014;1085:169-85. doi: 10.1007/978-1-62703-664-1_10.
- Staphylococcal superantigens (SAgs) comprise a large family of exotoxins produced by Staphylococcus aureus strains. These exotoxins are important in a variety of serious human diseases, including menstrual and nonmenstrual toxic shock syndrome (TSS), staphylococcal pneumonia and infective endocardit
- PMID 24085696
- Protecting against post-influenza bacterial pneumonia by increasing phagocyte recruitment and ROS production.
- Subramaniam R, Barnes PF, Fletcher K, Boggaram V, Hillberry Z, Neuenschwander P, Shams H.Author information Center for Pulmonary and Infectious Diseases Control (CPIDC).AbstractSeasonal and especially pandemic influenza predispose patients to secondary bacterial pneumonias, which are a major cause of deaths and morbidity. Staphylococcus aureus is a particularly common and deadly form of post-influenza pneumonia, and increasing staphylococcal drug resistance makes the development of new therapies urgent. We explored an innate immune-mediated model of the lung to define novel mechanisms by which the host can be protected against secondary staphylococcal pneumonia after sub-lethal influenza infection. We found that stimulating the innate immunity in the lung by overexpression of GM-CSF will result in resistance to S. aureus pneumonia after sublethal influenza infection. Resistance was mediated by alveolar macrophages and neutrophils, and was associated with increased production of reactive oxygen species (ROS) by alveolar macrophages. Resistance was abrogated by treatment with agents that scavenged ROS. We conclude that stimulating innate immunity in the lung markedly reduces susceptibility to post-influenza staphylococcal pneumonia and that this may represent a novel immunomodulatory strategy for prevention and treatment of secondary bacterial pneumonia after influenza.
- The Journal of infectious diseases.J Infect Dis.2013 Dec 29. [Epub ahead of print]
- Seasonal and especially pandemic influenza predispose patients to secondary bacterial pneumonias, which are a major cause of deaths and morbidity. Staphylococcus aureus is a particularly common and deadly form of post-influenza pneumonia, and increasing staphylococcal drug resistance makes the devel
- PMID 24367039
Japanese Journal
- Clinical Features of Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus in a Tertiary Hospital
- Yamada Koichi,Yanagihara Katsunori,Hara Yukiko,Araki Nobuko,Harada Yousuke,Morinaga Yoshitomo,Matsuda Junichi,Izumikawa Koichi,Seki Masafumi,Kakeya Hiroshi,Yamamoto Yoshihiro,Kohno Shigeru,Kamihira Shimeru
- The Tohoku Journal of Experimental Medicine 224(1), 61-67, 2011-05
- … Underlying disease, presumed source, MRSA sensitivity, Staphylococcal cassette chromosome mec (SCCmec) types, virulence genes and prognosis were evaluated. … Independent predictors associated with mortality in the multivariate analyses are pneumonia (P = 0.016), treatment with VCM (P = 0.039), and transplantation (P = 0.021). … VCM should not be selected when presumed source of MRSA bacteremia is pneumonia. …
- NAID 80021724808
- Hyper IgE Syndrome で発症したニューモシスチス肺炎の1例
- 窪田 素子,高柳 昇,倉島 一喜,宮原 庸介,原 健一郎,斉藤 大雄,徳永 大道,生方 幹夫,柳澤 勉,杉田 裕,河端 美則
- 日本呼吸器学会雑誌 = The journal of the Japanese Respiratory Society 45(5), 394-398, 2007-05-10
- NAID 10019479817
- Community-Acquired Staphylococcus aureus Pneumonia Accompanied by Rapidly Progressive Glomerulonephritis and Hemophagocytic Syndrome
- Hoshino Chisho,Satoh Noriyuki,Sugawara Shinichi,Kuriyama Chizuko,Kikuchi Akio,Ohta Masahiro
- Internal Medicine 46(13), 1047-1053, 2007
- … She was diagnosed as rapidly progressive glomerulonephritis and hemophagocytic syndrome associated with staphylococcal infection. … aureus producing TSST-1 and enterotoxin has been increasing and in cases of staphylococcal infections, close attention should be given to toxin-mediated as well as non-toxin-mediated clinical manifestations. …
- NAID 130000076166
Related Links
- Abstract A recent increase in staphylococcal infections caused by methicillin-resistant Staphylococcus aureus (MRSA), combined with frequent, prolonged ventilatory support of an aging, often chronically ill population, has ...
- Material and Results The total number of cases of staphylococcal pneumonia in adults recorded at the Johns Hopkins Hospital during the period from 1942 through 1956 was 18. From 1942 through 1949 there were only 4 cases ...
Related Pictures
★リンクテーブル★
| リンク元 | 「ブドウ球菌性肺炎」「ブドウ球菌肺炎」「黄色ブドウ球菌肺炎」 |
| 関連記事 | 「staphylococcal」 |
「ブドウ球菌性肺炎」
- 黄色ブドウ球菌による肺炎。
- 乳幼児に多い。近年は著しく減少している。
- 高頻度に膿胸を合併する。
- 重症化して肺の器質的障害を残しやすい。
- 胸部単純X線写真：気管支肺炎型(小葉性撒布病巣を呈する) or 多発性空洞型(多発性膿瘍形成を呈する)
「ブドウ球菌肺炎」
「黄色ブドウ球菌肺炎」
「staphylococcal」
- adj.
- ブドウ球菌性の、ブドウ球菌の